SGLT2 Inhibition for Reducing CVD Events in High-Risk T2DM SGLT2 Inhibition for Reducing CVD Events in High-Risk T2DM

This review examines the potential mechanisms by which SGLT2 inhibitors might impact cardiovascular risk. What role might they play in the treatment of diabetic patients at high CVD risk?European Heart Journal
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news